Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells

European Journal of Pharmaceutical Sciences

Volumn 45, Issue 3, 2012, Pages 272-281

  Takara, Kohji ^a   Fujita, Megumi ^b   Minegaki, Tetsuya ^b   Yamamoto, Kazuhiro ^b   Takahashi, Minoru ^a   Yokoyama, Teruyoshi ^a   Okumura, Katsuhiko ^a  

^a HIMEJI DOKKYO UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Cisplatin; Colorectal cancer; Oxaliplatin; Treatment schedule

Indexed keywords

CISPLATIN; DNA; DNA BINDING PROTEIN; FLUOROURACIL; OXALIPLATIN; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL KINETICS; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DRUG ANTAGONISM; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FLUOROURACIL; GENE EXPRESSION; HCT116 CELLS; HUMANS; MASS SPECTROMETRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 84855784690     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.11.023     Document Type: Article

References (27)

1. A.S. Abu-Surrah, and M. Kettunen Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin Curr. Med. Chem. 13 2006 1337 1357
2. S. Arnould, I. Hennebelle, P. Canal, R. Bugat, and S. Guichard Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines Eur. J. Cancer 39 2003 112 119 (Pubitemid 36005433)
3. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
4. M.P. Coleman, D. Forman, H. Bryant, J. Butler, B. Rachet, C. Maringe, U. Nur, E. Tracey, M. Coory, J. Hatcher, C.E. McGahan, D. Turner, L. Marrett, M.L. Gjerstorff, T.B. Johannesen, J. Adolfsson, M. Lambe, G. Lawrence, D. Meechan, E.J. Morris, R. Middleton, J. Steward, and M.A. Richards The ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data Lancet 377 2011 127 138
5. T. Esaki, S. Nakano, T. Tatsumoto, M. Kuroki-Migita, K. Mitsugi, M. Nakamura, and Y. Niho Inhibition by 5-fluorouracil of cis- diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line Cancer Res. 52 1992 6501 6506
6. D. Fink, S. Aebi, and S.B. Howell The role of DNA mismatch repair in drug resistance Clin. Cancer Res. 4 1998 1 6 (Pubitemid 28062870)
7. H. Fujishima, S. Nakano, N. Masumoto, T. Esaki, T. Tatsumoto, T. Kondo, and Y. Niho Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line Oncol. Res. 9 1997 167 172 (Pubitemid 127761183)
8. S. Hector, W. Bolanowska-Higdon, J. Zdanowicz, S. Hitt, and L. Pendyala In vitro studies on the mechanisms of oxaliplatin resistance Cancer Chemother. Pharmacol. 48 2001 398 406 (Pubitemid 33027997)
9. P.G. Johnston, F. Geoffrey, J. Drake, D. Voeller, J.L. Grem, and C.J. Allegra The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line Eur. J. Cancer 32 1996 2148 2154
10. Y. Kano, M. Akatsu, S. Tsunoda, T. Izumi, K. Mori, H. Fujii, Y. Yazawa, H. Mano, and Y. Furukawa Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro Cancer Chemother. Pharmacol. 54 2004 505 513 (Pubitemid 40022246)
11. N. Kitada, K. Takara, T. Minegaki, C. Itoh, M. Tsujimoto, T. Sakaeda, and T. Yokoyama Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines Cancer Chemother. Pharmacol. 62 2008 577 584
12. M. Kuroki, S. Nakano, K. Mitsugi, I. Ichinose, K. Anzai, M. Nakamura, S. Nagafuchi, and Y. Niho In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1 human squamous-carcinoma cell line Cancer Chemother. Pharmacol. 29 1992 273 276
13. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
14. L. Pendyala, and P.J. Creaven In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin Cancer Res. 53 1993 5970 5976 (Pubitemid 24006168)
15. B. Qin, R. Tanaka, Y. Shibata, S. Arita, H. Ariyama, H. Kusaba, E. Baba, M. Harada, and S. Nakano In vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines Anticancer Drugs 17 2006 445 453 (Pubitemid 44309988)
16. J.T. Reardon, A. Vaisman, S.G. Chaney, and A. Sancar Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro- cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts Cancer Res. 59 1999 3968 3971 (Pubitemid 29393563)
17. O. Rixe, W. Ortuzar, M. Alvarez, R. Parker, E. Reed, K. Paull, and T. Fojo Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel Biochem. Pharmacol. 52 1996 1855 1865 (Pubitemid 26419675)
18. M.L. Rothenberg, A.M. Oza, R.H. Bigelow, J.D. Berlin, J.L. Marshall, R.K. Ramanathan, L.L. Hart, S. Gupta, C.A. Garay, B.G. Burger, N. Le Bail, and D.G. Haller Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J. Clin. Oncol. 21 2003 2059 2069 (Pubitemid 46606353)
19. E.K. Rowinsky, M.R. Gilbert, W.P. McGuire, D.A. Noe, L.B. Grochow, A.A. Forastiere, D.S. Ettinger, B.G. Lubejko, B. Clark, and S.E. Sartorius Sequences of taxol and cisplatin: a phase I and pharmacologic study J. Clin. Oncol. 9 1991 1692 1703
20. G.G. Steel, and M.J. Peckham Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity Int. J. Radiat. Oncol. Biol. Phys. 5 1979 85 91 (Pubitemid 9120186)
21. K. Takara, N. Kitada, E. Yoshikawa, K. Yamamoto, S. Horibe, T. Sakaeda, K. Nishiguchi, N. Ohnishi, and T. Yokoyama Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride Cancer Lett. 278 2009 88 96
22. K. Takara, Y. Obata, E. Yoshikawa, N. Kitada, T. Sakaeda, N. Ohnishi, and T. Yokoyama Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel Cancer Chemother. Pharmacol. 58 2006 785 793 (Pubitemid 44351259)
23. T. Tanaka, H. Masuda, M. Naito, and H. Tamai Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line Anticancer Res. 21 2001 2463 2469 (Pubitemid 33054411)
24. J.M. Woynarowski, S. Faivre, M.C.S. Herzig, B. Arnett, W.G. Chapman, A.V. Trevino, E. Raymond, S.G. Chaney, A. Vaisman, M. Varchenko, and P.E. Juniewicz Oxaliplatin-induced damage of cellular DNA Mol. Pharmacol. 58 2000 920 927
25. M.D. Wyatt, and D.M. Wilson 3rd Participation of DNA repair in the response to 5-fluorouracil Cell. Mol. Life Sci. 66 2009 788 799
26. J.M. Xu, A. Azzariti, M. Severino, B. Lu, G. Colucci, and A. Paradiso Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin Biochem. Pharmacol. 66 2003 551 563 (Pubitemid 37281274)
27. S. Zhang, K.S. Lovejoy, J.E. Shima, L.L. Lagpacan, Y. Syu, A. Lapuk, Y. Chen, J.W. Gray, and X. Chen Organic cation transporters are determinants of oxaliplatin cytotoxicity Cancer Res. 66 2006 8847 8857 (Pubitemid 44449203)